| Briefly review physiology and known side effects of Glucagon-like peptide receptor agonists (GLP1RAs). |
|
|
|
|
|
|
| Evaluate data on which expanded indications, beyond type 2 diabetes and obesity, for use are based. |
|
|
|
|
|
|
| Implement GLP1RAs therapy in patients with appropriate indications. |
|
|
|
|
|
|